Ascletis Pharma Inc.

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
2020-09-09
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen
2020-08-20
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
2020-08-17
Ascletis’ All-oral HCV Treatment Approved for Marketing in China
2020-07-31
Bridging Study in China Completed for NASH Drug Candidate ASC40
2020-07-20
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
2020-06-17
Ascletis’THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
2020-05-13
Ascletis Receives IND Approval for its HIV Drug ASC09F
2020-04-13
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
2020-04-01
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients
2020-03-25

2

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1